Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Fig. 4

A EMPA reduced significantly the DOXO -induced ferroptosis in cardiac tissues, determined by Mitochondrial lipid peroxidation, measured using MitoPeDPP (ratio to sham). EMPA reduced significantly the DOXO -induced MDA content in cytosolic (B) and mitochondrial fraction (C) of cardiac tissues (ratio to sham). D EMPA reduced significantly the xanthine oxidase content in cardiac tissues during treatment with DOXO (mU/mg of protein). E EMPA exerts anti-inflammatory effects on the liver, heart and kidney of mice treated with DOXO. F EMPA reduces pro-inflammatory markers MyD88 and NLRP3 in cardiac tissue during DOXO treatments. For both, we quantified the expression of interleukin 1-β, interleukin 6 and interleukin 8 (pg/mg of protein) in heart, liver and left kidney lysates of mice untreated (Sham) or treated with EMPA, DOXO or DOXO/EMPA for 7 days (n = 6 for each group); in heart tissues only, we quantified the expression of MyD88 and NLRP3 through mouse ELISA kits (pg of marker/mg of protein). One-way ANOVA. Values are expressed ± SD.*** P < 0.001; **P < 0.01; *P < 0.05; ns: not significant

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840